公司发布的三季报数据显示，前三季公司共实现营业收入5.81亿元，同比下降4.06%，实现净利 润-4591.72万元，同比下降73.82%，基本每股收益为-0.0435元。（数据宝） （文章来源：证券时报网） 莱美药业11月25日披露，截至11月20日公司股东户数为30614户，较上期（11月10日）减少4399户，环 比降幅为12.56%。这已是该公司股东户数连续第3期下降。 证券时报·数据宝统计，截至发稿，莱美药业收盘价为5.01元，上涨2.04%，本期筹码集中以来股价累计 上涨0.80%。具体到各交易日，5次上涨，6次下跌。 融资融券数据显示，该股最新（11月24日）两融余额为2.00亿元，其中，融资余额为2.00亿元，本期筹 码集中以来融资余额合计减少603.83万元，降幅为2.93%。 ...

证券日报网讯莱美药业（300006）11月19日在互动平台回答投资者提问时表示，公司持续推进产品引进 工作，并获取了部分药械相关品种销售代理权。后续公司将进一步优化产品结构，加快产品与技术引 进，推动相关品种市场拓展。 ...

证券日报网讯莱美药业11月19日在互动平台回答投资者提问时表示，截至2025年11月10日，公司股东户 数为35013户。 （文章来源：证券日报） ...

格隆汇11月19日丨莱美药业(300006.SZ)在互动平台表示，公司主要聚焦抗肿瘤、消化系统及其他特色 专科药物等相关领域。 ...

每经AI快讯，有投资者在投资者互动平台提问：我正在研究医药行业企业在国家集采政策下的经营调 整策略。我发现贵公司近几年的应付账款周转天数有所增加，现有以下几个问题： 1、请问这一变化是 否存在受集采的影响？ 2、请问贵公司在集采中选后，是否曾经历过资金回笼或现金流方面的压力？ 3、公司采取了哪些管理或融资手段来缓解这一影响（是否有供应链金融、票据贴现或与上游供应商协 同）？ 莱美药业（300006.SZ）11月19日在投资者互动平台表示，集采政策对公司应付账款周转情况无影响， 当前公司现金状况合理充裕，无资金回笼压力。 （文章来源：每日经济新闻） ...

（文章来源：证券日报） 证券日报网讯莱美药业11月18日在互动平台回答投资者提问时表示，公司将持续关注控股股东所持公司 股份公开征集转让事宜。如有进展，公司将根据深交所相关规则及时披露进展公告。 ...

Core Viewpoint - Recently, Lai Mei Pharmaceutical, a subsidiary of Zhongheng Group, successfully won bids for multiple core products in national and Guangdong alliance drug procurement, showcasing the company's market competitiveness and laying a solid foundation for future market expansion [1][2] Group 1: National Drug Procurement - Lai Mei Pharmaceutical's Nicorandil tablets (5mg) were selected in the 11th batch of national drug centralized procurement, marking a significant entry into the mainstream medical market by 2025 [1] - The selection of Nicorandil tablets will provide strong support for sales and meet broader clinical needs, injecting new momentum into Lai Mei Pharmaceutical's high-quality development [1] Group 2: Guangdong Alliance Drug Procurement - Lai Mei Pharmaceutical achieved success in multiple rounds of Guangdong alliance drug procurement, with selected products covering various fields including anti-infective drugs, specialty medications, and basic infusion solutions [1] - The successful procurement results for drugs like Clindamycin injection and Triptorelin acetate injection further demonstrate the company's strong performance in the market [1] - In the procurement for common and chronic disease medications, Lai Mei Pharmaceutical's Cefoperazone dry suspension (50mg) was also successfully selected, enhancing drug accessibility [2] Group 3: Company Strength and Market Impact - The dual breakthroughs in national and provincial procurement reflect Lai Mei Pharmaceutical's comprehensive strength [2] - The selection of multiple products in centralized procurement accelerates the clinical accessibility of quality drugs, benefiting a wider patient population and reinforcing the company's brand influence in niche markets [2]

Core Points - On November 3, 2025, Laimei Pharmaceutical announced that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (referred to as "Guangxi Investment Group"), signed an "Equity Increase Agreement" and "Share Transfer Agreement" with Guangxi Investment Group Financial Holding Co., Ltd. (referred to as "Guangxi Financial Holding") [1] - Guangxi Investment Group plans to increase capital by transferring 859,343,587 shares (26.89% of the total share capital) of its holding in the controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (referred to as "Zhongheng Group"), to Guangxi Financial Holding [1] - The transfer has been confirmed for compliance by the Shanghai Stock Exchange and received a "Securities Transfer Registration Confirmation" from China Securities Depository and Clearing Co., Ltd. on November 3, 2025, with the transfer date being October 31, 2025 [1] - After the completion of the share transfer registration, Guangxi Financial Holding will become the indirect controlling shareholder of the company, while Zhongheng Group remains the direct controlling shareholder, and the actual controller of the company is still the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-055 重庆莱美药业股份有限公司 关于控股股东股权结构拟发生变动的进展暨 本次股份过户登记完成后，广投金控将变为公司间接控股股东，中恒集团仍 为公司直接控股股东，广西壮族自治区人民政府国有资产监督管理委员会仍为公 司实际控制人。本次股份转让事项，不会导致中恒集团对公司的控制权发生变更， 不会导致中恒集团持有公司股份数量和持股比例发生变化，亦不会对公司正常的 生产经营活动产生影响。 本次股份转让事项，不存在违反《上市公司收购管理办法》《上市公司股东 减持股份管理暂行办法》《上海证券交易所上市公司自律监管指引第 15 号—— 股东及董事、高级管理人员减持股份》《深圳证券交易所上市公司自律监管指引 第 18 号——股东及董事、高级管理人员减持股份》等有关法律法规和《公司章 程》相关规定的情形。 特此公告。 重庆莱美药业股份有限公司 本公司、董事会全体成员及相关股东保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 2025 年 9 月 26 日，重庆莱美药业股份有限公司（以下简称"公司"）间接控 股股东广西投资集 ...

Core Viewpoint - The company, Laimei Pharmaceutical, announced its participation in the 11th batch of national drug centralized procurement organized by the National Drug Procurement Office, with its product Nicorandil tablets expected to be selected in this procurement process [2] Group 1 - Laimei Pharmaceutical participated in the 11th batch of national drug centralized procurement [2] - The National Drug Procurement Office published the proposed selection results for the centralized procurement [2] - Nicorandil tablets from the company are expected to be selected in this procurement [2]